Rijkers Ger T, Yousif Laura Ie, Spoorenberg Simone Mc, van Overveld Frans J
Department of Science, University College Roosevelt, Middelburg, the Netherlands.
Department of Medical Microbiology and Immunology, St. Antonius Hospital, Nieuwegein, the Netherlands.
Risk Manag Healthc Policy. 2018 Mar 27;11:55-65. doi: 10.2147/RMHP.S130405. eCollection 2018.
Pneumococcal pneumonia is a serious disease with considerable morbidity and mortality in the elderly. Despite adequate antibiotic treatment, the long-term mortality of pneumococcal pneumonia remains high. Preventive measures in the form of vaccination, therefore, are warranted. Twenty-three-valent polysaccharide vaccines have a broad coverage but limited efficacy. Pneumococcal conjugate vaccines have been shown in children to be able to prevent invasive and mucosal pneumococcal diseases. It should be realized that the serotype composition of current pneumococcal conjugate vaccines is not tailored for the elderly, and that replacement disease can occur. Yet, the current 13-valent conjugate vaccine has been shown to protect against infections with vaccine serotypes. Long-term mortality of pneumococcal pneumonia should be included in policy making about the introduction of these vaccines for the elderly.
肺炎球菌肺炎是一种严重疾病，在老年人中具有相当高的发病率和死亡率。尽管进行了充分的抗生素治疗，肺炎球菌肺炎的长期死亡率仍然很高。因此，以疫苗接种形式的预防措施是必要的。23价多糖疫苗覆盖面广但效力有限。肺炎球菌结合疫苗已在儿童中显示出能够预防侵袭性和黏膜性肺炎球菌疾病。应该认识到，目前的肺炎球菌结合疫苗的血清型组成并非针对老年人量身定制，可能会发生替代疾病。然而，目前的13价结合疫苗已显示出能预防疫苗血清型感染。在制定针对老年人引入这些疫苗的政策时，应将肺炎球菌肺炎的长期死亡率考虑在内。
